scholarly journals Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded Tissues

2009 ◽  
Vol 57 (5) ◽  
pp. 477-489 ◽  
Author(s):  
Dimo Dietrich ◽  
Ralf Lesche ◽  
Reimo Tetzner ◽  
Manuel Krispin ◽  
Jörn Dietrich ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Ductal Carcinoma ◽  
Treatment Protocol ◽  
Tumor Infiltrating Lymphocytes ◽  
Tissue Samples ◽  
Bisulfite Treatment ◽  
Pcr Product ◽  
Reliable Quantification ◽  
Infiltrating Lymphocytes ◽  
Formalin Fixed

A procedure for simultaneous quantification of DNA methylation of several genes in minute amounts of sample material was developed and applied to microdissected formalin-fixed and paraffin-embedded breast tissues. The procedure is comprised of an optimized bisulfite treatment protocol suitable for samples containing only few cells, a multiplex preamplification and subsequent locus specific reamplification, and a novel quantitative bisulfite sequencing method based on the incorporation of a normalization domain into the PCR product. A real-time PCR assay amplifying repetitive elements was established to quantify low amounts of bisulfite-treated DNA. Ten prognostic and diagnostic epigenetic breast cancer bio-markers ( PITX2, RASSF1A, PLAU, LHX3, PITX3, LIMK1, SLITRK1, SLIT2, HS3ST2, and TFF1) were analyzed in tissue samples obtained from two patients with invasive ductal carcinoma of the breast. The microdissected samples were obtained from several areas within the tumor tissue, including intraductal and invasive carcinoma, adenosis, and normal ductal epithelia of adjacent normal tissue, as well as stroma, tumor infiltrating lymphocytes, and adipose tissue. Overall, reliable quantification was possible for all genes. For most genes, increased DNA methylation in invasive and intraductal carcinoma cells compared with other tissue components was observed. For TFF1, decreased methylation levels were observed in tumor cells. (J Histochem Cytochem 57:477–489, 2009)

scholarly journals Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ

2021 ◽  
Vol 10 (1) ◽  
pp. 1875637
Author(s):  
Fei-Fei Xu ◽  
Sai-Fang Zheng ◽  
Cheng Xu ◽  
Gang Cai ◽  
Shu-Bei Wang ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

scholarly journals iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3276
Author(s):  
Alexandra Giatromanolaki ◽  
Avgi Tsolou ◽  
Eleftheria Daridou ◽  
Maria Kouroupi ◽  
Katerina Chlichlia ◽  
...  
Keyword(s):  
Immune Response ◽  
Overall Survival ◽  
Small Cell Lung Carcinoma ◽  
Expression Patterns ◽  
Tumor Infiltrating Lymphocytes ◽  
Small Cell ◽  
Small Cell Lung ◽  
Tissue Samples ◽  
Cell Lung Carcinoma ◽  
Infiltrating Lymphocytes

Background: Inducible Nitric Oxygen Synthase (iNOS) promotes the generation of NO in tissues. Its role in tumor progression and immune response is unclear. Methods: The immunohistochemical expression patterns of iNOS were studied in a series of 98 tissue samples of non-small-cell lung carcinoma (NSCLC), in parallel with the expression of hypoxia and anaerobic metabolism markers, PD-L1 and tumor-infiltrating lymphocytes (TILs). Results: iNOS is expressed by cancer cells in 19/98 (19.4%), while extensive expression by cancer-associated fibroblasts occurs in 8/98 (8.2%) cases. None of these patterns relate to stage or prognosis. Extensive infiltration of the tumor stroma by iNOS-expressing TILs (iNOS+TILs) occurs in 47/98 (48%) cases. This is related to low Hypoxia-Inducible Factor 1α (HIF1α), high PD-L1 expression and a better overall survival (p = 0.002). Expression of PD-L1, however, mitigates the beneficial effect of the presence of iNOS+TIL. Conclusions: Extensive expression of iNOS by TILs occurs in approximately 50% of NSCLCs, and this is significantly related to an improved overall survival. This brings forward the role of iNOS in anti-neoplastic lymphocyte biology, supporting iNOS+TILs as a putative marker of immune response. The value of this biomarker as a predictive and treatment-guiding tool for tumor immunotherapy demands further investigation.

Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

2018 ◽  
Vol 31 (7) ◽  
pp. 1012-1025 ◽  
Author(s):  
Marie Colombe Agahozo ◽  
Dora Hammerl ◽  
Reno Debets ◽  
Marleen Kok ◽  
Carolien H M van Deurzen
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS)

2019 ◽  
Vol 26 (10) ◽  
pp. 3337-3343 ◽  
Author(s):  
Farbod Darvishian ◽  
Ugur Ozerdem ◽  
Sylvia Adams ◽  
Jennifer Chun ◽  
Elizabeth Pirraglia ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

scholarly journals The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

2017 ◽  
Vol 28 (2) ◽  
pp. 321-328 ◽  
Author(s):  
G. Pruneri ◽  
M. Lazzeroni ◽  
V. Bagnardi ◽  
G.B. Tiburzio ◽  
N. Rotmensz ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Clinical Relevance ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

scholarly journals CD 8 + tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER 2‐positive ductal carcinoma in situ

2016 ◽  
Vol 5 (7) ◽  
pp. 1607-1618 ◽  
Author(s):  
Michi Morita ◽  
Rin Yamaguchi ◽  
Maki Tanaka ◽  
Gary M. Tse ◽  
Miki Yamaguchi ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Tumor Infiltrating Lymphocytes ◽  
Spontaneous Healing ◽  
Her 2 ◽  
Infiltrating Lymphocytes

scholarly journals Prognostic Value of Tumor-Infiltrating Lymphocytes in DCIS: A Meta-Analysis

2021 ◽  
Author(s):  
Shuang-Ling Wu ◽  
Xinmiao Yu ◽  
Xiaoyun Mao ◽  
Feng Jin
Keyword(s):  
Systematic Review ◽  
Predictive Value ◽  
Ductal Carcinoma ◽  
Data Extraction ◽  
Meta Analysis ◽  
Tumor Infiltrating Lymphocytes ◽  
Recurrence Risk ◽  
Assessment Method ◽  
Infiltrating Lymphocytes

Abstract BackgroundTumor infiltrating lymphocytes (TILs) have been demonstrated to be associated with the prognosis of breast ductal carcinoma in situ (DCIS). In this systematic review and meta-analysis, we investigated the role of TILs and TIL subsets in predicting the recurrence risk of DCIS.MethodPubMed, Medline, Web of Science, Embase and Cochrane were searched to identify publications investigating the prognostic role of TILs in DCIS. After study screening, data extraction and risk of bias assessment, a meta-analysis was performed to assess the association between TILs (total TILs, CD4+, CD8+, FOXP3+, PD-L1+ TILs) and the risk of DCIS recurrence.ResultsA pooled analysis indicated that dense stromal TILs in DCIS were associated with a higher recurrence risk (HR 2.11 (95% CI 1.35-3.28)). Subgroup analysis showed that touching TILs (HR 4.73 (95% CI 2.28-9.80)) was more favorable than the TIL ratio (HR 1.49 (95% CI 1.11-1.99)) in estimating DCIS recurrence risk. Moreover, the predictive value of TILs is suitable for patients who are diagnosed with DCIS and then undergo surgery (HR 2.77, (95% CI 1.26-6.07)) or surgery accompanied by radiotherapy (HR 2.26, (95% CI 1.29-3.95)), but not for patients who receive comprehensive adjuvant therapies (HR 1.16, (95% CI 1.35-3.28)). Among subsets of TILs, dense stromal PD-L1+ TILs were valuable in predicting higher recurrence risk of DCIS.ConclusionThis systematic review and meta-analysis confirmed the predictive value of TILs and stromal PD-L1+ TILs in DCIS and indicated an appropriate assessment method for TILs and an eligible population.

Sign in / Sign up

Export Citation Format

Share Document